vTv Therapeutics(US:VTVT)2025-11-06 21:26Financial Performance - vTv Therapeutics reported a net loss of $8.7 million or $1.08 per basic share for Q3 2025, compared to a net loss of $4.8 million or $0.88 per basic share in Q3 2024[6]. - Total operating expenses for Q3 2025 were $10.7 million, compared to $6.5 million in Q3 2024[10]. - vTv Therapeutics' accumulated deficit reached $319.55 million as of September 30, 2025, compared to $299.72 million at the end of 2024[8]. Cash Position - The company's cash position increased to $98.5 million as of September 30, 2025, up from $36.7 million at the end of 2024[5]. - The total liabilities increased to $28.95 million as of September 30, 2025, from $23.97 million at the end of 2024[8]. Research and Development - Research and development expenses rose to $7.0 million in Q3 2025, compared to $3.2 million in Q3 2024, reflecting increased spending on cadisegliatin and other projects[6]. - vTv Therapeutics successfully completed an $80 million private placement in September 2025 to fund the ongoing CATT1 Phase 3 trial[5]. - The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025, with topline data expected in the second half of 2026[5]. - The company anticipates reporting topline results from the CATT1 trial in the second half of 2026[2]. Intellectual Property - The U.S. Patent and Trademark Office allowed claims for a new patent covering crystalline forms of cadisegliatin, with exclusivity expected until 2041[5].